Neuromuscular adverse events

Research output: Contribution to journalArticle

Abstract

Neuromuscular adverse events (AEs) associated with cancer treatment with immune checkpoint inhibitors (ICIs) include diverse clinical subsets. The general features of neuromuscular AEs have not been elucidated because the frequency is generally low, ranging from 1-2% of cancer patients undergoing ICIs therapy. The diseases affect the central nervous system, peripheral nerves, neuromuscular junction, and muscle. Disease onset and progression may be rapid with a critical clinical course. The clinical presentation may be different from that of patients unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and mild treatment-related AEs. In contrast, representative immune-related AEs such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and myositis were serious. There was a tight association between myasthenia, myositis, and myocarditis. There are guidelines for the treatment of neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, checkpoint inhibitor therapy should be withheld until the nature of the AEs is defined. Immune-modulating medication is generally effective for neuromuscular AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is required for the best management of cancer patients.

Original languageEnglish
Pages (from-to)1036-1040
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume45
Issue number7
Publication statusPublished - 2018 Jul 1

Fingerprint

Myositis
Dysgeusia
Second Primary Neoplasms
Polyneuropathies
Neuromuscular Junction
Central Nervous System Diseases
Myocarditis
Dizziness
Therapeutics
Peripheral Nerves
Autoantibodies
Headache
Disease Progression
Neoplasms
Guidelines
T-Lymphocytes
Muscles
Pharmaceutical Preparations
Hashimoto's encephalitis

Keywords

  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Myasthenia gravis
  • Myositis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neuromuscular adverse events. / Suzuki, Shigeaki.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 45, No. 7, 01.07.2018, p. 1036-1040.

Research output: Contribution to journalArticle

@article{0640a74b151d4c889e6bdf3bafe1548f,
title = "Neuromuscular adverse events",
abstract = "Neuromuscular adverse events (AEs) associated with cancer treatment with immune checkpoint inhibitors (ICIs) include diverse clinical subsets. The general features of neuromuscular AEs have not been elucidated because the frequency is generally low, ranging from 1-2{\%} of cancer patients undergoing ICIs therapy. The diseases affect the central nervous system, peripheral nerves, neuromuscular junction, and muscle. Disease onset and progression may be rapid with a critical clinical course. The clinical presentation may be different from that of patients unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and mild treatment-related AEs. In contrast, representative immune-related AEs such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and myositis were serious. There was a tight association between myasthenia, myositis, and myocarditis. There are guidelines for the treatment of neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, checkpoint inhibitor therapy should be withheld until the nature of the AEs is defined. Immune-modulating medication is generally effective for neuromuscular AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is required for the best management of cancer patients.",
keywords = "Immune checkpoint inhibitors, Immune-related adverse events, Myasthenia gravis, Myositis",
author = "Shigeaki Suzuki",
year = "2018",
month = "7",
day = "1",
language = "English",
volume = "45",
pages = "1036--1040",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "7",

}

TY - JOUR

T1 - Neuromuscular adverse events

AU - Suzuki, Shigeaki

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Neuromuscular adverse events (AEs) associated with cancer treatment with immune checkpoint inhibitors (ICIs) include diverse clinical subsets. The general features of neuromuscular AEs have not been elucidated because the frequency is generally low, ranging from 1-2% of cancer patients undergoing ICIs therapy. The diseases affect the central nervous system, peripheral nerves, neuromuscular junction, and muscle. Disease onset and progression may be rapid with a critical clinical course. The clinical presentation may be different from that of patients unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and mild treatment-related AEs. In contrast, representative immune-related AEs such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and myositis were serious. There was a tight association between myasthenia, myositis, and myocarditis. There are guidelines for the treatment of neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, checkpoint inhibitor therapy should be withheld until the nature of the AEs is defined. Immune-modulating medication is generally effective for neuromuscular AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is required for the best management of cancer patients.

AB - Neuromuscular adverse events (AEs) associated with cancer treatment with immune checkpoint inhibitors (ICIs) include diverse clinical subsets. The general features of neuromuscular AEs have not been elucidated because the frequency is generally low, ranging from 1-2% of cancer patients undergoing ICIs therapy. The diseases affect the central nervous system, peripheral nerves, neuromuscular junction, and muscle. Disease onset and progression may be rapid with a critical clinical course. The clinical presentation may be different from that of patients unrelated to drugs. Headache, dizziness, and dysgeusia were relatively common and mild treatment-related AEs. In contrast, representative immune-related AEs such as autoimmune encephalitis, demyelinating polyneuropathy, myasthenia, and myositis were serious. There was a tight association between myasthenia, myositis, and myocarditis. There are guidelines for the treatment of neuromuscular immune-mediated AEs. For all but the minimum neurological symptoms, checkpoint inhibitor therapy should be withheld until the nature of the AEs is defined. Immune-modulating medication is generally effective for neuromuscular AEs. Both CD8+ cytotoxic T-cells and autoantibodies are involved in the pathogenesis of neuromuscular AEs. Correct understanding of neuromuscular AEs is required for the best management of cancer patients.

KW - Immune checkpoint inhibitors

KW - Immune-related adverse events

KW - Myasthenia gravis

KW - Myositis

UR - http://www.scopus.com/inward/record.url?scp=85053015276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053015276&partnerID=8YFLogxK

M3 - Article

C2 - 30042267

AN - SCOPUS:85053015276

VL - 45

SP - 1036

EP - 1040

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 7

ER -